First Light Asset Management
Edina, MNfiles as First Light Asset Management, LLC
$1.6bn in 31 US stocks at the end of 30 June 2026. The top 10 are 60.7% of the money. It changed about 23.2% of the portfolio this quarter.
Value
$1.6bn
Stocks
31
Top 10 share
60.7%
Turnover
23.2%
What changed this quarter
New
Bought for the first time this quarter.
- Trevi TherapeuticsTRVI2.4% of the fund
- Tactile Systems TechnologyTCMD0.8% of the fund
Added
Bought more of a stock they already held.
- NeogenomicsNEO10.9% of the fund+26%
- Si-BoneSIBN8.1% of the fund+52%
- Apogee TherapeuticsAPGE7.5% of the fund+61%
- Enliven TherapeuticsELVN4.2% of the fund+574%
- Guardant HealthGH4.0% of the fund+58%
- 908 DevicesMASS3.3% of the fund+3%
- GeneDx HoldingsWGS3.3% of the fund+223%
- Simulations PlusSLP3.1% of the fund+6%
- Tandem Diabetes CareTNDM3.1% of the fund+157%
- Crinetics PharmaceuticalsCRNX3.1% of the fund+25%
- NeuroPaceNPCE2.8% of the fund+16%
- Edgewise TherapeuticsEWTX2.7% of the fund+9%
- AnaptysbioANAB2.4% of the fund+3%
- SepternaSEPN2.0% of the fund+31%
- TriSalus Life SciencesTLSI1.8% of the fund+29%
- Tectonic TherapeuticTECX1.7% of the fund+24%
- VaxcytePCVX1.2% of the fund+143%
Cut
Sold some of their stake.
- AxogenAXGN7.7% of the fund-31%
- Palvella TherapeuticsPVLA7.2% of the fund-21%
- Twist BioscienceTWST4.6% of the fund-17%
- Amylyx PharmaceuticalsAMLX3.3% of the fund-5%
- Establishment Labs HoldingsESTA1.3% of the fund-20%
- OmnicellOMCL1.1% of the fund-8%
- AtriCureATRC1.0% of the fund-22%
- KORU Medical SystemsKRMD0.9% of the fund-10%
Sold out
Sold their entire stake.
- Centessa Pharmaceuticals-100%
- Wave Life SciencesWVE-100%
- Vera TherapeuticsVERA-100%
- Mimedx GroupMDXG-100%
- SpyGlass PharmaSGP-100%
- Organogenesis HoldingsORGO-100%
Holdings
- Apogee TherapeuticsAPGE
- Share
- 7.5%
- Value
- $123m
- Shares
- 930,289
+61%
- Crinetics PharmaceuticalsCRNX
- Share
- 3.1%
- Value
- $51m
- Shares
- 1,360,866
+25%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| NeogenomicsNEO | 10.9% | $179m | 12,279,523 | +26% |
| Si-BoneSIBN | 8.1% | $133m | 8,127,985 | +52% |
| AxogenAXGN | 7.7% | $127m | 2,748,361 | -31% |
| Apogee TherapeuticsAPGE | 7.5% | $123m | 930,289 | +61% |
| Palvella TherapeuticsPVLA | 7.2% | $118m | 771,901 | -21% |
| Twist BioscienceTWST | 4.6% | $75m | 727,933 | -17% |
| Enliven TherapeuticsELVN | 4.2% | $69m | 1,360,750 | +574% |
| Guardant HealthGH | 4.0% | $66m | 441,586 | +58% |
| 908 DevicesMASS | 3.3% | $55m | 6,282,804 | +3% |
| Amylyx PharmaceuticalsAMLX | 3.3% | $54m | 3,023,256 | -5% |
| GeneDx HoldingsWGS | 3.3% | $54m | 783,923 | +223% |
| Simulations PlusSLP | 3.1% | $51m | 2,792,677 | +6% |
| Tandem Diabetes CareTNDM | 3.1% | $51m | 3,383,553 | +157% |
| Crinetics PharmaceuticalsCRNX | 3.1% | $51m | 1,360,866 | +25% |
| NeuroPaceNPCE | 2.8% | $45m | 2,861,167 | +16% |
| Edgewise TherapeuticsEWTX | 2.7% | $44m | 1,095,171 | +9% |
| AnaptysbioANAB | 2.4% | $39m | 582,004 | +3% |
| Trevi TherapeuticsTRVI | 2.4% | $39m | 2,097,215 | New |
| SepternaSEPN | 2.0% | $32m | 963,260 | +31% |
| TriSalus Life SciencesTLSI | 1.8% | $30m | 6,552,491 | +29% |
| Tectonic TherapeuticTECX | 1.7% | $28m | 800,726 | +24% |
| Health CatalystHCAT | 1.5% | $25m | 12,810,861 | Held |
| Butterfly NetworkBFLY | 1.4% | $22m | 2,642,404 | Held |
| Establishment Labs HoldingsESTA | 1.3% | $21m | 246,577 | -20% |
| VaxcytePCVX | 1.2% | $20m | 345,157 | +143% |
| iRhythm HoldingsIRTC | 1.2% | $20m | 167,092 | Held |
| OmnicellOMCL | 1.1% | $19m | 452,324 | -8% |
| AtriCureATRC | 1.0% | $16m | 567,838 | -22% |
| KORU Medical SystemsKRMD | 0.9% | $14m | 3,387,902 | -10% |
| Tactile Systems TechnologyTCMD | 0.8% | $14m | 462,562 | New |
| Rhythm PharmaceuticalsRYTM | 0.6% | $10m | 85,765 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 113.3% since 30 June 2025.
Where the money is
Health care83.3%
Industrials10.9%
Technology5.8%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.